文献速递胸部肿瘤

莫博赛替尼治疗铂类经治EGFR外显子20插入突变转移性非小细胞肺癌的疗效与安全性

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-12-16

该1/2期开放标签非随机试验评估莫博赛替尼160mg每日一次治疗铂类经治EGFR外显子20插入突变转移性非小细胞肺癌,PPP队列114例确认客观缓解率28%(95%CI 20%-37%),中位无进展生存7.3个月,中位总生存24.0个月,常见治疗相关不良事件为腹泻和皮疹,安全性可控。

要点

  • 铂类经治EGFRex20ins转移性NSCLC中,莫博赛替尼IRC确认ORR为28%。
  • 中位缓解持续时间17.5个月,中位PFS 7.3个月,中位OS 24.0个月。
  • 最常见治疗相关不良事件为腹泻和皮疹,安全性总体可控。

核心结论

  • 在铂类经治EGFRex20ins阳性转移性NSCLC患者中,莫博赛替尼显示出具有临床意义的获益,且安全性可控。

研究设计与样本

  • 研究为3部分、开放标签、1/2期非随机临床试验,包含剂量递增/扩展队列(美国28个中心)和单臂扩展队列EXCLAIM(亚洲、欧洲和北美40个中心),于2016年6月至2020年11月(数据截止日)开展。
  • 主要分析人群为铂类经治患者(PPP)队列和EXCLAIM队列;PPP队列纳入114例铂类经治EGFRex20ins阳性转移性NSCLC患者,接受莫博赛替尼160mg每日一次,来自剂量递增(n=6)、剂量扩展(n=22)和EXCLAIM(n=86)队列。
  • EXCLAIM队列纳入96例既往经治EGFRex20ins阳性转移性NSCLC患者,其中10例未接受过铂类治疗而被排除于PPP队列。

主要发现

  • PPP队列(n=114)中位年龄60岁(范围27-84),女性75例(66%),亚洲种族68例(60%);中位随访14.2个月,中位既往抗癌方案数2线,基线脑转移40例(35%)。
  • PPP队列经IRC评估确认ORR为28%(95%CI 20%-37%),研究者评估确认ORR为35%(95%CI 26%-45%)。
  • PPP队列经IRC评估中位缓解持续时间为17.5个月(95%CI 7.4-20.3),中位无进展生存期为7.3个月(95%CI 5.5-9.2),中位总生存期为24.0个月(95%CI 14.6-28.8)。
  • EXCLAIM队列(n=96)中位年龄59岁(范围27-80),女性62例(65%),亚洲种族66例(69%);中位随访13.0个月,经IRC评估确认ORR为25%(95%CI 17%-35%),研究者评估确认ORR为32%(95%CI 23%-43%)。
  • 最常见的治疗相关不良事件为腹泻和皮疹。

临床怎么用

  • 对于铂类经治的EGFRex20ins阳性转移性NSCLC患者,莫博赛替尼160mg每日一次可作为治疗选择之一,需关注腹泻和皮疹等不良反应。

局限性

  • 本研究为开放标签、非随机、单臂设计,缺乏随机对照比较。
  • PPP队列和EXCLAIM队列样本量分别为114例和96例,部分亚组分析可能受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Metastatic non-small cell lung cancer (mNSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral tyrosine kinase inhibitor designed to selectively target EGFRex20ins mutations. OBJECTIVE: To evaluate treatment outcomes and safety of mobocertinib in patients with previously treated EGFRex20ins-positive mNSCLC. DESIGN, SETTING, AND PARTICIPANTS: This 3-part, open-label, phase 1/2 nonrandomized clinical trial with dose-escalation/dose-expansion cohorts (28 sites in the US) and a single-arm extension cohort (EXCLAIM; 40 sites in Asia, Europe, and North America) was conducted between June 2016 and November 2020 (data cutoff date). The primary analysis populations were the platinum-pretreated patients (PPP) cohort and the EXCLAIM cohort. The PPP cohort included 114 patients with platinum-pretreated EGFRex20ins-positive mNSCLC who received mobocertinib 160 mg once daily from the dose-escalation (n = 6), dose-expansion (n = 22), and EXCLAIM (n = 86) cohorts. The EXCLAIM cohort included 96 patients with previously treated EGFRex20ins-positive mNSCLC (10 were not platinum pretreated and thus were excluded from the PPP cohort). INTERVENTIONS: Mobocertinib 160 mg once daily. MAIN OUTCOMES AND MEASURES: The primary end point of the PPP and EXCLAIM cohorts was confirmed objective response rate (ORR) assessed by independent review committee (IRC). Secondary end points included confirmed ORR by investigator, duration of response, progression-free survival, overall survival, and safety. RESULTS: Among the PPP (n = 114) and EXCLAIM (n = 96) cohorts, the median (range) age was 60 (27-84) and 59 (27-80) years, respectively; most patients were women (75 [66%] and 62 [65%], respectively) and of Asian race (68 [60%] and 66 [69%], respectively). At data cutoff, median follow-up was 14.2 months in the PPP cohort (median 2 prior anticancer regimens; 40 [35%] had baseline brain metastases), with confirmed ORR of 28% (95% CI, 20%-37%) by IRC assessment and 35% (95% CI, 26%-45%) by investigator assessment; median duration of response by IRC assessment was 17.5 months (95% CI, 7.4-20.3). Median progression-free survival by IRC assessment was 7.3 months (95% CI, 5.5-9.2). Median overall survival was 24.0 months (95% CI, 14.6-28.8). In the EXCLAIM cohort, median follow-up was 13.0 months, with confirmed ORR by IRC assessment of 25% (95% CI, 17%-35%) and by investigator assessment of 32% (95% CI, 23%-43%). The most common treatment-related adverse events were diarrhea and rash. CONCLUSIONS AND RELEVANCE: In this open-label, phase 1/2 nonrandomized clinical trial, mobocertinib was associated with clinically meaningful benefit in patients with previously treated EGFRex20ins-positive mNSCLC, with a manageable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02716116.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou C, Ramalingam SS, Kim TM, et al. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021. PMID: 34647988. doi:10.1001/jamaoncol.2021.4761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。